Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Vertex Pharmaceuticals
Biotech
Vertex races to FDA after phase 3 kidney disease data impress
The phase 3 win for povetacicept met analyst expectations and fired the starting gun on a race to the FDA that could result in a November approval.
Nick Paul Taylor
Mar 10, 2026 6:20am
Sarepta CEO to step down as DM1 hits home—Chutes & Ladders
Feb 27, 2026 8:30am
FDA reveals 2nd round of 'national priority' voucher winners
Nov 6, 2025 3:12pm
Vertex boosts artillery with $2B-plus Enlaza pact
Sep 2, 2025 10:26am
Altos ascends with new clinical leader—Chutes & Ladders
Aug 8, 2025 8:30am
Vertex drops asset in acute pain after phase 2 fail
Aug 4, 2025 5:34pm
